Tempus AI, Inc. (TEM), a healthcare technology company that applies artificial intelligence to precision medicine, has become one of the most closely watched names in the health-data space. After reaching a 52-week high of $104.32 in late 2025, shares pulled back sharply and have recently traded near $59, roughly in the middle of their 52-week range of $40.77 to $104.32. That leaves the $80 stock price target as a meaningful, widely discussed milestone: it sits well above the current price but well below the prior peak, and it is the most frequently cited bullish objective among analysts covering the company.
Tempus operates a vertically integrated platform that combines genomic sequencing, laboratory diagnostics, and a repository of de-identified clinical and molecular data. Its revenue comes primarily from oncology diagnostics (next-generation sequencing and hereditary testing) and from a data and applications business that licenses insights to pharmaceutical partners such as AstraZeneca, GSK, Merck, Bristol Myers Squibb, and BioNTech. The company was founded in 2015 by CEO Eric Lefkofsky, is headquartered in Chicago, and completed its initial public offering in June 2024.
The most compelling bull case rests on accelerating commercial momentum. In the second quarter of 2026, Tempus reported revenue of $382.5 million, up 22% year over year, and delivered GAAP net income of $5.6 million—its first profitable quarter—alongside positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). Management raised full-year 2026 revenue guidance to between $1.595 billion and $1.605 billion, implying roughly 25% growth.
Two catalysts stand out. First, the company received FDA approval for its tumor-only xT CDx test, allowing migration to higher-priced ADLT (Advanced Diagnostic Laboratory Test) pricing, which management estimates will add about $85 million in annual revenue beginning in 2027. Second, the pending acquisition of PSNL (Personalis) is expected to strengthen Tempus's position in minimal residual disease (MRD) testing, a market the company sizes at more than $20 billion. Several analysts have framed the deal as a key driver of their bullish ratings.
Despite the recent profitability milestone, Tempus remains unprofitable on a trailing twelve-month basis, with a negative net margin and negative trailing EPS. Its valuation is demanding relative to current earnings, and the stock carries a beta near 3.7, indicating volatility far above the broader market. Insider selling has also drawn attention: company insiders sold more than one million shares worth roughly $57 million over a recent 90-day period, including sales under pre-arranged trading plans.
Sentiment is split. While many analysts have raised targets, others remain cautious—Stifel holds a $50 target, J.P. Morgan is at $45 with a Hold rating, and Jefferies initiated coverage with a Sell rating and a $35 target. The wide dispersion from $35 to $100 reflects genuine uncertainty about the durability of Tempus's margins and growth.
The consensus analyst price target for Tempus AI is approximately $67.59, implying about 14.5% upside from current levels, with ratings skewing toward Buy. The bullish cluster is notable: Cantor Fitzgerald, BTIG, Canaccord Genuity, and Raymond James all carry $80 targets, while Piper Sandler upgraded the stock to Overweight with a $76 target and Mizuho holds the Street-high $100 objective. The $80 stock price target therefore represents a realistic but above-consensus scenario that aligns with the more optimistic end of analyst coverage.
From a technical analysis perspective, the $80 level functions as a psychological round number and a supply zone where prior buying interest stalled after the 2025 selloff. Before reaching it, the stock would likely need to reclaim the $67–$70 range, which coincides with the consensus analyst target and has acted as resistance. On the downside, support appears near the 200-day moving average around $52 and the 50-day average near $56, with more substantial support at the $40.77 52-week low. A sustained break above $70 would strengthen the case for a move toward $80, while a failure to hold $52 would undermine the bullish setup.
Traders tracking Tempus AI's price action may also benefit from automated tools such as Tickeron's AI Daily Buy/Sell Signals. This product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual review alone. Investors interested in a data-driven approach to timing entries and exits may find these AI Daily Buy/Sell Signals a useful complement to their own research.
Can Tempus AI reach $80? The evidence suggests it is achievable but far from assured. The strongest supports are accelerating revenue, a path to positive free cash flow, FDA-related pricing upside, and a strategic acquisition that could meaningfully expand the company's addressable market. The primary obstacles are a still-negative trailing bottom line, an elevated valuation, heavy insider selling, and a volatile trading profile. Investors should watch the integration of Personalis, progress on ADLT pricing, quarterly margin trends, and whether shares can hold the $52–$56 support zone while challenging the $67–$70 resistance area. A decisive move through $70 would mark an important step toward the $80 stock price target, while any deterioration in growth or margin trajectory would likely push that objective further away.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TEM has been loosely correlated with SDGR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if TEM jumps, then SDGR could also see price increases.
| Ticker / NAME | Correlation To TEM | 1D Price Change % | ||
|---|---|---|---|---|
| TEM | 100% | +0.24% | ||
| SDGR - TEM | 58% Loosely correlated | +4.20% | ||
| TXG - TEM | 52% Loosely correlated | +3.26% | ||
| GEHC - TEM | 40% Loosely correlated | +1.06% | ||
| LFMD - TEM | 35% Loosely correlated | +0.16% | ||
| OMDA - TEM | 33% Poorly correlated | +0.88% | ||
More | ||||
| Ticker / NAME | Correlation To TEM | 1D Price Change % |
|---|---|---|
| TEM | 100% | +0.24% |
| Services to the Health Industry industry (42 stocks) | 26% Poorly correlated | +0.29% |
| Health Services industry (242 stocks) | 2% Poorly correlated | -0.34% |